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Table 1. Absolute (mg) and body weight adjusted (mg/g) liver and kidney weights in normal and uremic rats
Treatment group Body weight (g)a Liver wt (mg) Liver wt (mg/g) Kidney wt (mg) Kidney wt (mg/g)
La[−] control 472 11,632 24.6 1489 3.2
La[+] control 463 11,004 23.8 1430 3.1
La[−] adenine 340 9003 26.5 2420 7.1
La[+] adenine 307 7114 23.2 2092 6.8
La[−] Nx 330 8899 27.0 810 2.5
La[+] Nx 307 7829 25.5 727 2.4
Abbreviations: [−], no lanthanum treatment; [+], 3% lanthanum in diet; Nx, 5/6th nephrectomized renal failure model; adenine, adenine induced renal failure model
(adenine given 0.3% of diet); control, normal renal function. Body weight adjustment abolishes differences in organ weight between lanthanum-treated and -untreated
groups within each renal failure model.
aNonfasted preterminal body weight (day 38) extracted from Figure 1 of Lacour et al [1].
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The need for careful
interpretation of animal data
on lanthanum
To the Editor: Lacour et al [1] describe reductions in
organ weights in uremic rats given lanthanum carbon-
ate, those for liver and kidney being highlighted as sig-
nificant because differences remained after normalisa-
tion for femur length. Adjustment using femur length
is unconventional, as drug effects on body mass (un-
less they affect growth) do not influence this parameter.
Normalization using body mass is the standard method,
and in our view should have been used due to the dif-
ferences in body weight between lanthanum-treated and
-untreated rats. When kidney and liver weights are nor-
malized in this way, group differences are abolished (see
Table 1 above).
The authors also note qualitative differences in tissue
lanthanum deposition between normal and uremic rats,
and between different uremia models. No hypotheses
were put forward to suggest why lanthanum might de-
posit in brain, heart, and skeletal muscle in one disease
model, but not in another, or in normal rats. The extent
to which these differences were artefacts of contamina-
tion is unclear, as lanthanum was administered at very
high concentrations in the diet (probably powdered), and
plasma concentrations were extraordinarily high both in
control and lanthanum-treated groups [2]. Lung depo-
sition is also unusual in our experience and may reflect
inhalation of lanthanum from the diet. Furthermore, the
authors report major intestinal pathology in the adenine
uremia model, but not the nephrectomized model, yet
paradoxically rule out any influence of this on the ab-
sorption and deposition of lanthanum.
Extrapolation of the Lacour et al [1] findings to human
lanthanum exposure appears unwarranted at this time.
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Reply from the Authors
We agree with Rambeck that the usual way of compar-
ing organ weights of uremic animals with those of nor-
mal animals is normalization for body mass, not femur
length. However, because in our study we happened to
observe markedly lower liver weights in the two animal
groups with chronic renal failure (CRF) fed on lanthanum
carbonate, we compared CRF rats receiving lanthanum
treatment with CRF rats receiving no lanthanum treat-
ment [1]. Thus, in doing this analysis we did not compare
CRF rats with normal rats. Because total body weights
were also slightly decreased in the two groups of CRF
rats that received lanthanum supplements, as compared
to those CRF rat groups receiving no lanthanum sup-
plements, we reasoned that the changes in liver weight
should be better normalized using total femur length,
which remained the same, than using total body weight,
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which changed slightly. More important, for a reasonable
interpretation of our findings, we have proceeded to do a
formal comparison of liver weight after normalization for
total body weight, using analysis of variance (ANOVA).
This analysis showed not only a significant group effect
that is lower body weights in CRF versus no CRF groups
(P < 0.001), but also a significant treatment effect that is
lower body weights in lanthanum versus no lanthanum
treatment (P < 0.022), with no interaction. In addition,
ANOVA also showed significant effects of both group
and treatment on liver weight (P < 0.001 and <0.001),
and heart weight (p < 0.001 and <0.017). In contrast,
although there was a significant group effect on brain,
lung, and femur weight (P < 0.001), there was no lan-
thanum treatment effect on the weight of these two tis-
sues. When normalizing the organ weights for total body
weight, ANOVA showed significant effects of both group
and treatment on liver weight (P < 0.038 and < 0.004),
brain weight (P < 0.001 and <0.009), and femur weight
(P < 0.001 and <0.047), whereas only group effects were
seen for heart and lung weights (both P < 0.001).
The results of these ANOVAs confirm our previous
observations of a deleterious effect of prolonged admin-
istration of high amounts of lanthanum carbonate on liver
weight, as shown in Table 1 of our study [1], using post-
hoc tests to make comparisons easily understandable, and
extends them to total body weight and that of other or-
gans. This demonstrates that the rough analysis made by
Rambeck (see Table) based on body weights approxi-
mated from Figure 1 of our article led him to reach an
erroneous conclusion. Because he did not have access
to individual values for the calculation of possible group
effects, we wonder how he could claim that the signifi-
cant effects of lanthanum administration on liver weight
disappeared after correction of organ weights for body
weight.
Concerning Rambeck’s remark on quantitative (not
qualitative) differences in tissue lanthanum deposition
between rat groups we would like to offer the following
answers. (1) Lanthanum content in renal tissue has been
expressed per g dry weight, as it has been for all other
tissues examined. Expressed in this way, lanthanum con-
tent is significantly higher in kidneys from lanthanum-
overloaded CRF rats after subtotal nephrectomy (Nx)
than in kidneys from lanthanum-overloaded CRF rats
after exposure to adenine (see Fig. 4F of our paper [1]).
However, considering the fact that the mean weight of
the remaining renal tissue after bipolar left Nx and con-
tralateral total Nx in lanthanum-overloaded rats was only
727 mg (fresh wet weight), as compared to a mean to-
tal renal tissue mass of 2092 mg (fresh wet weight) in
adenine-treated rats with lanthanum overload, the actual
total mean amount of lanthanum accumulated in renal tis-
sue was roughly the same between the two groups, namely
29.5 ng per total kidney mass (wet weight) in Nx rats and
27.9 ng per total kidney mass (wet weight) in adenine-
treated rats. (2) The extremely high plasma lanthanum
concentrations in all rats groups are due to a regrettable
error in the units used (see detailed explanation above
given to McLeod et al). (3) We have no easy explanation
for the variations of lanthanum concentrations observed
in different tissues between rats with normal renal func-
tion and CRF rats, and between the two different CRF
models used, except the 3 to 30 times greater accumu-
lation in the liver than in the other organs. Because the
liver is the first organ exposed to lanthanum after its in-
testinal absorption, and because mean liver lanthanum
concentrations were above 1200 ng/g dry weight in the
two CRF models, in contrast to mean lanthanum concen-
trations below 400 ng/g dry weight in all other organs,
it is reasonable to assume that the liver performed its
usual function of trapping absorbed compounds during
first passage. Alternatively, one could also hypothesize a
possible role of adenine overload in favoring lanthanum
absorption and/or tissue deposition and retention. How-
ever, we failed to observe a specific adenine treatment
effect.
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Consideration of use of
neuraminidase inhibitors such
as oseltamivir and zanamivir in
IgA nephropathy
To the Editor: IgA nephropathy (IgAN) is the most
common glomerulonephritis worldwide. Nonspecific
treatments such as steroids are unfortunately often not
particularly efficacious in IgAN and, as the pathogene-
sis of the disease has remained obscure, specific treat-
ment has been lacking. Recently, Xu and Zhao [1] have
found aberrantly glycosylated serum IgA1 in IgAN. In
particular, they find that the IgA1 in IgAN patients with
